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The Indian pharmaceutical sector is large and has the 
potential of a global leader for low-priced high-quality 
drugs. The new patent regulations had a strong impact 
on the drug industry in India. There is a serious decline 
in the number of pharma patents recently after com-
pulsory licensing for drugs was implemented in India. 
While regulations are meant for reducing the prices of 
essential drugs, there are investment-related issues 
when a patent is subjected to voluntary licensing. The 
present study focuses on three phases in pharmaceuti-
cal patenting identified by analysing the major patent 
databases and the potential shift in pharma patenting 
sector from acute to lifestyle disease-based drugs. The 
recent trend identified in the pharma patenting sector 
in India is quite unusual and unreported so far. 
Keywords: Compulsory licensing, generic drug market, 
Indian pharma market, lifestyle diseases, pharma patent-
ing trends. 
THE past two decades have revolutionized patenting and 
licensing in the Indian pharmaceutical sector. There has 
been a drastic development in this field due to high 
demand for generic drugs in developed countries, patent 
expiry and the growing importance of biologics. In 2015, 
the Indian pharma market was dominated by generic 
drugs (71%) followed by over-the-counter (OTC) medi-
cines (19%) and patented drugs (10%). Demand for pat-
ented branded drugs has declined due to growing 
importance of generic drugs. In 2010, the share of paten-
ted drugs was 70% in the global market, which declined 
to 53% in 2015 (ref. 1). Between 2006 and 2015, a total 
of 67,342 patents were granted in India, of which 56,727 
were foreign and 10,615 were Indian inventors. There has 
been a gradual decrease in patents filed in the Indian 
patent office during the past 5 years2. According to the 
World Intellectual Property Organization (WIPO) Global 
Innovation Index-2015, of the 141 economies surveyed in 
the world, India ranked 81st in position3. Indian compa-
nies are among world leaders in the production of gener-
ics and vaccines. India accounted for 20% of the global 
generic market by volume in 2010, which increased to 22% 
in 2015. Of late, generic manufacturers are facing problems 
in manufacture and supply of generic versions of new pat-
ented medicines resulting in an increase in the dependency 
of imported expensive medicines, which has disturbed the 
Indian pharma generic market4. 
 The present study analyses pharma patenting in India 
for the past two decades and classifies the sector into 
three phases. The increase in sale of drugs for lifestyle 
diseases has boosted the Indian pharmaceutical sector. 
The drug trends for 5 major lifestyle diseases during 
2010–2015 are also analysed. 
Data source and methodology 
The primary information for analysis of patenting trends 
with respect to pharmaceuticals in India was compiled 
from Indian Patent Advanced Search System (InPASS) 
patent search using the search option – Field of invention: 
(FI11) Pharmaceuticals. Information on generic drugs, 
biologics/biopharma drugs, marine drugs, biosimilars and 
lifestyle diseases was obtained from Espacenet database. 
The secondary information was collected from various 
printable and non-printable sources, such as search engines, 
news and government websites, online journals, white 
papers, magazines, company reports, books and other 
accessible databases. Data available on top International 
Patent Classification (IPC) codes, top assignees, legal 
status and the patents reported in different technology 
domains in pharma patenting were analysed using 
Questel – ‘Orbit’ software. Technology domains for non-
steroidal anti-inflammatory drugs (NSAIDs), anti-cancer 
drugs and anti-diabetes drugs related patents were also 
examined. The software provides a comprehensive suite 
of tools to analyse individual databases, make database 
clusters and merge them into a single database. 
Results and discussion 
Indian scenario – pharmaceutical patenting activity 
trend 
The regulations governing pharma patenting sector in 
India enable citizens to access medicines at cheaper prices.
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Figure 1. a, Indian pharma patenting trend (Source: InPASS data). b, Global pharma patenting trend 
(Source: Espacenet Data). 
 
The Indian patent system underwent different amend-
ments to realize this aim and the government took strong 
measures, such as compulsory licensing, enabling the  
Indian pharma patenting. The Indian Patent Act was for-
mulated in 1970, which allowed process patent protection 
for chemicals and pharmaceutical products for a short 
span of 7 years. Prior to this act, the global multinational 
manufacturers controlled the Indian pharmaceuticals 
market. The process patent act encouraged the Indian 
domestic market to manufacture essential drugs leading 
to a boom in the production of generic drugs. Till date, 
India is the largest provider of generic drugs globally. In 
the past two decades, the pharma patenting regime in  
India has undergone a parabolic shift (Figure 1 a) based 
on which it has been classified into three phases. 
Phase I (1995–2005) 
Generic drugs prevailed in the Indian pharmaceutical 
market. This was in tune with the process patent domain 
initiated since the Indian Patent Act 1970. The research 
and development (R&D) fund allocation decreased during 
this phase as the domestic pharmaceutical companies did 
not invest in R&D to develop new and innovative thera-
peutic drugs. The focus of the Indian pharmaceutical 
companies during this phase was to manufacture generic 
versions of patented drugs. As a result, India became a 
source of cheap generic drugs for supply to the third 
world and other developing countries. The Indian health-
care system immensely benefited during this phase with 
cheaper generic drugs when compared to similar versions 
in the global market. 
Phase II (2006–2010) 
The Indian government introduced product patents under 
the Patents (Amendment) Act, 2005 to spur more R&D 
activities in India and to encourage both domestic and 
multinational firms. The product patents facilitated the 
global pharma companies to bring their patented products 
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to India, which led to the transfer of technologies in the 
pharmaceutical sector from developed nations. More 
pharma patenting was reported during this period in India 
(Figure 1 a). Globally more investments were made in 
R&D activities during this phase, opening new areas of 
research, such as biotechnology, bioinformatics, bio-
pharmaceuticals, etc. Drugs from natural biological 
sources were attaining relevance, which led to the emer-
gence of biologics and biosimilars. Domestic companies 
were unable to invest heavily in R&D of new innovative 
drugs. Subsequently, Indian companies started licensing 
arrangements, such as out-licensing of molecules or  
in-licensing of competent molecules with multinational 
companies to develop novel drugs. In the meantime,  
generic drug companies, which dominated the domestic 
market started to export generic versions of off-patent 
drugs. Towards the end of this phase, it was observed that 
generic drugs continued to rule the domestic pharma 
market accounting for 20% of the global generic market; 
there was an increase in the number of pharma patents 
published and the evolution of biologics and biosimilars 
in India. 
Phase III (2011–2015) 
This is a new phase observed in the pharma patenting 
sector of India. The increase in number of pharma patents 
in the second phase led to an increase in the price of 
pharmaceutical drugs. There was a hue and cry for regu-
lating the prices of critical drugs, such as anti-cancer 
drugs in India leading to internal issues in the Indian 
health care system. After a few deliberations, it was de-
cided to regulate the drug prices by compulsory licensing 
of few drugs; for example in 2012, India issued a com-
pulsory license for Bayer’s cancer drug Nexavar to Natco 
Pharma to produce a generic version of Nexavar, citing 
concerns that the drug was not accessible to patients in 
the country5. Compulsory licensing is a license issued by 
the state authority to a company violating the rights of the 
patent holder. This became a debated issue in the drug 
patenting circle at an international level. Many compa-
nies, who had the patented products in India, raised  
severe objections to compulsory licensing. There are re-
ports on the onset of compulsory licences for three more 
anti-cancer patented drugs, i.e. dasatinib, ixabepilone and  
trastuzumab. The uprising of compulsory licensing set an 
impulse for voluntary licensing in the Indian pharma 
market. The voluntary licensing agreement between the 
original drug maker and a local or retail drug producer is 
an exclusive manufacturing and marketing alliance6. The 
pharmaceutical companies are adopting this as a business 
strategy, which has recently raised concerns in the Indian 
pharma market. For example, a voluntary license agree-
ment was signed between 11 Indian generic drug produc-
ers and Gilead Science to bring the blockbuster Hepatitis 
C drug Sovaldi to Indian markets. Although 49 million 
Hepatitis C patients live in middle-income countries, the 
voluntary license prevents export of the generic drug to 
middle-income countries. This may curb the growth of 
Indian generic market. ‘The Indian government has  
expressed concern that India will no more be the ‘phar-
macy of the world’ if generic companies ‘gave up’ the 
fight for access to affordable drugs’4. There was a de-
crease in pharma patenting trends towards the end of this 
phase (Figure 1 a). Issuing compulsory license for inter-
national drugs could be a reason. The number of granted 
pharma patents during 2013–2015 was nil; the reason 
could be less number of patent examiners compared to 
the rise in number of pharma patents filed. Though there 
are concerns with respect to the growth of the generic 
market in future, the generic drugs continue to dominate 
the Indian pharma market. 
Global scenario of pharmaceutical patenting 
The data on pharmaceutical patenting globally for the last 
two decades was obtained from Espacenet database. 
There was an increase in pharmaceutical patenting trend 
at the global level when compared to India (Figure 1 b). 
During the first phase (1995–2005), there was a gradual 
increase till 2000; subsequently, there was an exponential 
increase in patenting trend till 2005. During 2006–2010 
(second phase) the pharma patenting trend was found to 
be almost stationary at global level. The third phase 
(2011–2015) indicates a surge in global pharma patenting 
trend. 
 Apart from branded patented drugs, the other catego-
ries of drugs in pharmaceutical market were bio-
pharma/biologics, generic, biosimilar and marine drugs. 
The data for patents filed during the past 20 years for the 
process or products related to these drugs were taken 
from Espacenet. From the data (Figure 2 a), it could be 
inferred that other than branded patented drugs, the num-
ber of patents related to generic drugs was high compared 
to other categories of drugs. Patenting in biopharmaceuti-
cals emerged in 2002, which has gained importance and 
continued to grow till 2015. Over the past two decades, 
limited patenting activity has been reported related to ma-
rine pharma drugs and biosimilars. 
Lifestyle diseases 
In the Indian pharmaceutical sector, drugs for acute dis-
eases dominated, but recently, with increasing urbaniza-
tion and modern style of living, about 50% of expenditure 
related to pharmaceutical drugs is for lifestyle diseases. 
The World Health Organization (WHO) survey states that 
about 60% of the total mortality reported annually in  
India is due to lifestyle-related diseases, such as cardio-
vascular diseases 26%, diabetes 2%, respiratory diseases
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Figure 2. a, Global pharma patenting in different categories of drugs (Source: Espacenet data).  
b, Patenting trends for five major lifestyle diseases (Source: Espacenet data). 
 
 
13%, cancer 7%, others 12% (ref. 7). Patel et al.8 fore-
casted that around 75% of all deaths in India will be due 
to chronic lifestyle diseases in 2030. Cancer fatalities will 
rise to 1.5 million, cardiovascular deaths to 4 million, and 
coronary heart disease deaths to 17.9 million in 2030 (ref. 
9). The surge in lifestyle diseases in India has boosted the 
sale of drugs for chronic diseases such as diabetics, on-
cology, cardiovascular, etc. Apart from chemical formu-
lation of drugs, marine nutraceuticals and drugs have also 
contributed towards the cure of different lifestyle diseases. 
The pharma patenting trends for drugs on five major life-
style diseases, i.e. cancer, diabetes, inflammatory, hyper-
tensive and hyperthyroidism drugs, in the past five years 
were analysed from the data obtained from Espacenet 
(Figure 2 b). 
Anticancer drugs 
The global anti-cancer drug market had reached 100  
billion USD in 2014 and could reach 147 billion USD by 
2018 (ref. 10). Global players such as Roche, Novartis, 
Pfizer and others dominated the oncology drug market. 
The major companies in India producing anti-cancer 
drugs are Cipla limited, Sun Pharma and Dr Reddy  
Laboratories. With growing awareness on treatment of 
cancer, there has been a greater influx in anti-cancer 
drugs11. Recently, the major global companies in onco-
logy have started to pursue potential combination thera-
pies for cancer. Over the past five years, the highest 
number of patents relating to anti-cancer drugs were filed 
in 2014 (Figure 2 b). The oncology drug market gained 
more attention at the international level when compared 
to other lifestyle diseases in the current study. 
Anti-diabetic drugs 
Based on rapid growth in diabetes incidences globally, 
the International Diabetes Federation forecasted an  
increase up to 552 million USD by 2030 (ref. 12). The 
global spending on diabetes has increased by 47% during 
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the past five years (2010–2015)11. During this period, 
anti-diabetes drugs topped pharma sales in India. In 2015, 
the anti-diabetes drugs grew at 32.9% by value among 
different segments of the Indian pharmaceutical market13. 
The most prescribed anti-diabetes drug is a combination 
of glimepiride and metformin, marketed as Glycomet GP 
and Gluconorm-G (ref. 14). The domestic market of anti-
diabetes drug is ruled by major foreign companies, such 
as Novo Nordisk, Eli Lily and GlaxoSmithKline. The  
increase in urbanization and health insurance policies for 
diabetes has boosted the anti-diabetes drug market in  
India. The R&D activities for novel anti-diabetes drugs 
have led to the emergence of biologics in this arena.  
Various biopharmaceutical drugs for diabetes are under-
going clinical trials. Lately, in 2015, a marine nutraceuti-
cal ‘CadalminTM ADe’ from seaweeds was patented in 
India, which has active ingredients to act against type-II 
diabetes15. At the global level the anti-diabetes drugs  
related patenting trends were high in 2013 and 2014  
according to data obtained from Espacenet (Figure 2 b). 
Anti-inflammatory drugs 
The global anti-inflammatory therapeutics market is ex-
pected to grow at a rate of 5.9% from 2014 to 2020. Anti-
inflammatory biologics are more effective and have lesser 
side effects when compared to the conventional drugs. 
Anti-inflammatory drugs include drugs for arthritis, res-
piratory diseases, multiple sclerosis, psoriasis, inflamma-
tory bowel disease, etc. Anti-inflammatory biologics are 
the most preferred drugs for the treatment of arthritis. It 
accounts for 54.8% share of the global anti-inflammatory 
therapeutics market16. India had lately filed a patent for a 
product ‘CadalminTM GMe’, a marine anti-inflammatory 
biologic having bioactive ingredients extracted from 
green mussel Perna viridis to combat inflammatory dis-
eases, such as arthritis, joint pain, etc. Marine nutraceuti-
cals, such as ‘CadalminTM GAe’ from seaweeds or marine 
macroalgae (seaweeds) also contain ingredients to treat 
inflammatory pain and arthritis17. There has been a decline 
in the patenting trends related to anti-inflammatory drugs 
during the past five years (Figure 2 b). The highest num-
ber of patents filed were in 2010 followed by a rapid  
decrease during 2011–2015. There are initiatives, such as 
‘drugs from the sea’ campaign for utilizing the bio-active 
properties from resources of marine origin, which can re-
place costlier terrestrial counterparts in bio-similar drugs. 
Anti-hypertensive drugs 
At the global level, the pharma market analysts had fore-
casted that antihypertensive drug market will grow at  
a compound annual growth rate (CAGR) of 1.2% from 
2013 to 2018 (ref. 18). Some of the major anti-
hypertensive drug patents such as Diovan expired, which 
led to a decline in the growth of the antihypertensive 
market. The current status of anti-hypertensive drug un-
der the cardiovascular segment represents 13% of the  
Indian pharma market13. Lately, with the prevalence of 
lifestyle diseases, the cardiovascular segment is the third 
major sector in the Indian pharma market that has gained 
attention for R&D activities. Despite fluctuations in the 
patenting trends of anti-hypertensive drugs over the past 
five years, its contribution is likely to rise due to increase 
in the number of patients suffering from hypertension. 
During 2010–2015, the highest number of patents related 
to anti-hypertensive drugs was filed (Figure 2 b). 
Hyperthyroidism drugs 
The occurrence of thyroid disorders differs according to 
geographical distribution, diet, nutrition and population. 
 
 
 
 
 
Figure 3. a, Top five IPC classes of pharmaceutical patents. b, Top 
ten global pharma patent assignees. c, Legal status of pharma patent 
applications. 
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Figure 4. Technology domains: a, Pharmaceuticals; b, NSAIDs. 
 
Globally, thyroid disorders – hypothyroidism and hyper-
thyroidism, influence about 5–10% of the population. The 
global market for treatment of thyroid gland disorders was 
1.8 billion USD in 2014, and is predicted to reach 2.4 bil-
lion USD in 2023. The major companies in global thyroid 
gland disorder market are Abbott Laboratories, AbbVie, 
Mylan NV, Pfizer, GlaxoSmithKline, Merck KGaA, Novar-
tis AG and Sanofi19. In India, hypothyroidism has an upper 
hand over hyperthyroidism, and is more prevalent among 
females (66.4%) than males (33.6%)20. The patents filed re-
lating to hyperthyroidism drugs were lower in comparison 
with other lifestyle diseases considered in the present 
study. Fewer number of patents filed was observed in  
intermittent years, i.e. 2010, 2012 and 2014 (Figure 2 b). 
Questel – ‘orbit’ data findings 
Data on the top five IPC classes in pharma patent applica-
tions were analysed (Figure 3 a). The majority of the 
pharmaceutical related patents was filed in Class A61P, 
i.e. specific therapeutic activity or chemical compounds 
for medical preparations, followed by class A61K, i.e. 
preparations for medical, dental or toilet purposes. The
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Figure 5. Technology domains: a, anti-cancer drugs; b, anti-diabetes drugs. 
 
legal status of the pharma patent applications (Figure 3 b) 
indicated that out of a total of 5,45,612 pharma patent  
applications, 34% have been granted, 25% lapsed without 
examination, 22% pending to be examained, 11% expired 
and 7% revoked. The top 10 pharma patent assignees 
were examined (Figure 3 c); the three major assignees 
were Pfizer – 10,191 applications, Merck Sharp and 
Dohme – 8955 and GlaxoSmithkline – 8938. 
 Questel – ‘Orbit’ has categorized the patents under 35 
technology domains based on IPC classes and subclasses. 
The distribution of pharmaceutical patents and non-
steroidal anti-inflammatory drug (NSAIDs) patents under 
different technological domains was carried out. NSAIDs 
data were taken to characterize and analyse the patents 
correlating lifestyle diseases, because inflammation is the 
causal agent for majority of diseases, such as diabetes, 
cancer, arthritis, etc. The main technology domain having 
the maximum number of patents was ‘pharmaceutical’, 
which was depicted in red colour in the honeycomb graph 
(Figure 4 a and b). The other technological domains  
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under which a considerable number of patents catego-
rized were (i) organic fine chemistry, (ii) analysis of bio-
logical materials, (iii) biotechnology, (iv) basic materials 
chemistry, (v) medical technology and (vi) food chemis-
try, and highlighted as yellow coloured cells in the figure. 
The empty cells in the figure represent the technology 
domains having no reports of patents related to pharma-
ceuticals and NSAIDs. The rapid growth of anti-cancer 
drugs and anti-diabetes drugs in the global market, has  
attained relevance as the two major lifestyle diseases  
affecting people. Reports of patents related to anti-cancer 
drugs and anti-diabetes drugs under various technology 
domains were analysed and illustrated in Figure 5 a and b 
respectively. 
Concluding remarks 
The Indian health care system had a slow growth com-
pared to global scenario. During the last two decades, the 
pharma patenting trends in India experienced a parabolic 
shift with lag phase, log phase and declining phase. Even 
though the pharma patenting has reduced, revenue from 
the pharma market has constantly increased making India 
one of the top 10 pharma markets globally. Marine phar-
maceutical drugs have the potential for using cheaper  
input ingredients, which can replace the existing costly 
drugs. As ingredient prices come down, biosimilar drugs 
will become cheaper. This study emphasizes the impor-
tance of major investments in biosimilar drugs, particu-
larly from the marine sector for emerging lifestyle 
diseases. 
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